Company Overview

Gain Therapeutics, Inc. is a biotechnology company focused on developing small-molecule therapeutics designed to restore the function of misfolded proteins associated with rare and neurodegenerative diseases. The company operates within the biotechnology and precision medicine industries, with a strategic emphasis on disorders linked to protein instability and lysosomal dysfunction. Its core technology platform, known as Magellan™, is a computational drug discovery engine intended to identify allosteric binding sites and develop pharmacological chaperones that stabilize proteins and improve cellular trafficking and function.

The company’s primary revenue and value driver is its therapeutic pipeline, particularly programs targeting Parkinson’s disease associated with GBA1 mutations and other lysosomal storage disorders. GT-02287, its lead investigational candidate, is being developed for Parkinson’s disease with GBA1 mutations, a genetically defined subset of Parkinson’s patients. Gain Therapeutics was founded in 2017 and has evolved from a platform-focused computational biology company into a clinical-stage biotechnology enterprise advancing proprietary therapeutic candidates through preclinical and clinical development.

Business Operations

Gain Therapeutics conducts operations primarily through research and development activities centered on its proprietary Magellan™ platform and its pipeline of small-molecule pharmacological chaperones. The company generates no significant commercial product revenue as of publicly available filings and instead relies primarily on capital raised through equity offerings and financing activities to fund operations. Its principal business segment is drug discovery and development targeting central nervous system disorders and lysosomal diseases.

The company maintains operations in both the United States and Europe, with activities including computational chemistry, preclinical biology, clinical development, and regulatory engagement. Gain Therapeutics has utilized collaborations with academic institutions, contract research organizations, and specialized development partners to support research and clinical execution. The company’s asset base is centered on proprietary intellectual property, computational modeling capabilities, and therapeutic candidates designed to penetrate the central nervous system and address protein misfolding mechanisms.

Strategic Position & Investments

Gain Therapeutics’ strategic direction is focused on leveraging its computational platform to develop disease-modifying therapies for neurodegenerative and rare genetic disorders with high unmet medical need. The company has concentrated investment toward advancing GT-02287 through clinical development while expanding research into additional lysosomal storage and protein-folding disorders. Public disclosures and investor materials indicate that Gain Therapeutics views precision medicine and genetically stratified patient populations as a central component of its development strategy.

The company has also invested in expanding the applications of the Magellan™ platform beyond Parkinson’s disease, including exploratory work involving Gaucher disease and other disorders linked to lysosomal dysfunction. Gain Therapeutics’ strategic positioning is differentiated by its focus on allosteric modulation and protein stabilization rather than traditional enzyme replacement or symptomatic treatment approaches. Data regarding material acquisitions or large-scale portfolio investments is inconclusive based on available public sources.

Geographic Footprint

Gain Therapeutics maintains a transatlantic operational presence, with corporate headquarters in Bethesda, Maryland, United States, and additional operations historically associated with Europe, including scientific and research activities connected to Spain. The company’s development and research network involves collaborations and operational support across multiple international jurisdictions, reflecting the global nature of biotechnology research and clinical development.

Its market and investor presence is primarily concentrated in the United States, where its shares trade publicly on the Nasdaq Capital Market under the ticker GANX. The company also engages with clinical research organizations and scientific partners across North America and Europe to support development programs and regulatory activities.

Leadership & Governance

Gain Therapeutics is led by executives with backgrounds in biotechnology, pharmaceuticals, drug development, and computational science. The company’s leadership has emphasized advancing precision therapeutics through computationally enabled discovery approaches and targeted development in neurodegenerative diseases. Public company filings and investor communications consistently describe a strategy centered on platform scalability, disciplined capital allocation, and progression of clinical-stage assets.

Key executives and leadership figures include:

• Gene Mack – Interim Chief Executive Officer
• Eric Richman – Chairman of the Board
• João Siffert, M.D. – President of Research and Development
• Catherine S. Tsai, Ph.D. – Chief Scientific Officer
• Hans Schikan – Member of the Board of Directors

Leadership and governance information has been verified against publicly available company filings, investor materials, and market disclosures. Some executive roles and board memberships may change over time based on subsequent corporate filings.